Shyamsundar Rajan, MD
Geriatric Medicine · Silver Spring, MDNPI 1093730442
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $462 and has fallen 67.5% since, to $150 in 2025.
Across 107 payments — averaging $18.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$408
- Novo Nordisk$301
- Lilly USA, LLC$280
- Boehringer Ingelheim$268
- GSK$157
- Merck$153
- plus $428 from 7 others
What the payments were for
- Food & beverage$1,987100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $408 |
| Novo Nordisk | 16 | $301 |
| Lilly USA, LLC | 14 | $280 |
| Boehringer Ingelheim | 14 | $268 |
| GSK | 9 | $157 |
| Merck | 9 | $153 |
| Novartis | 5 | $103 |
| Sunovion Pharmaceuticals Inc. | 4 | $69 |
| Pfizer | 4 | $68 |
| Exact Sciences | 3 | $66 |
| Gilead | 3 | $64 |
| AbbVie | 1 | $32 |
| Bayer | 1 | $27 |
How this compares
$1,995 in reported general payments places this provider in the 80th percentile of 112 geriatric medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $98,522 |
| JardianceEmpagliflozin | 80 | $97,075 |
| TradjentaLinagliptin | 49 | $40,635 |
| OzempicSemaglutide | 22 | $35,788 |
| FarxigaDapagliflozin Propanediol | 28 | $32,763 |
| EliquisApixaban | 28 | $32,341 |
| JanuviaSitagliptin Phosphate | 29 | $23,485 |
| EntrestoSacubitril/Valsartan | 24 | $20,885 |
| TrulicityDulaglutide | 15 | $19,931 |
| MyrbetriqMirabegron | 22 | $10,239 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $9,031 |
| VerquvoVericiguat | 13 | $8,288 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,495 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $6,303 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 84 | $3,466 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $268 | $137,710129 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta | $157 | $114,049141 claims |
| Novo NordiskOzempic | $301 | $35,78822 claims |
| AstraZenecaFarxiga | $408 | $32,76328 claims |
| PfizerEliquis | $68 | $32,34128 claims |
| MerckJanuvia, Verquvo | $153 | $31,77242 claims |
| NovartisEntresto | $103 | $20,88524 claims |
| Lilly USA, LLCTrulicity | $280 | $19,93115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 112 geriatric medicine providers in Maryland.
Other geriatric medicine in Silver Spring
- Mitra HashemiSilver Spring$5K
- Xiao Chun YangSilver Spring$2K
- Ruth Kevess-CohenSilver Spring$167
- Sean LengBaltimore$412K
- Jocelyn El-SayedBaltimore$84K
- Joanne LynnChevy Chase$52K
- James LettRockville$33K
- Marcelino AlbuerneCatonsville$14K
- Lee MusherChevy Chase$13K
- Raman TuliGaithersburg$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.